Cardiol Therapeutics filed a preliminary short form base shelf prospectus with Canadian securities regulators and a corresponding Form F-10 registration statement with the U.S. Securities and Exchange Commission under the Multijurisdictional Disclosure System. The filings could allow the company to offer up to US$150 million of common shares, debt securities, warrants, subscription receipts, units or combinations of those securities over a 25-month period after the final prospectus receipt is issued and the registration statement becomes effective. No securities are being offered through the announcement, and the filing does not require Cardiol to conduct an offering. At the request of Ontario Securities Commission staff, the prospectus also adds program-level research and development cost and timing data, expense breakdowns, and details comparing the intended and actual use of proceeds from an October 2024 financing. Cardiol said its Phase III MAVERIC trial of CardiolRx in recurrent pericarditis is nearing target enrollment, while Phase II ARCHER results in acute myocarditis and development of CRD-38 support its broader heart-disease pipeline.